What is the PRE stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Prenetics Global Ltd. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PRE stock a buy right now?
Of the 3 analysts covering Prenetics Global Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prenetics Global Ltd. 39 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PRE?
As at 6 Aug 2026, Prenetics Global Ltd. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
Will PRE stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +96.0% from the last close, and Ticker Nerd's factor model ranks Prenetics Global Ltd. 39 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PRE stock forecast for 2030?
No analyst covering Prenetics Global Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
What does Prenetics Global Ltd. do?
Prenetics Global Limited is a health sciences company headquartered in Hong Kong that specializes in early detection, prevention, and treatment of diseases, particularly cancer, through genomic testing and wellness solutions. The company operates three primary business segments: Prevention, through CircleDNA, a direct-to-consumer genetic testing brand utilizing next-generation sequencing technology to provide comprehensive health and wellness insights; Diagnostics, through ACT Genomics, which offers precision oncology testing services and became the first Asia-based company to receive FDA clearance for comprehensive genomic profiling of solid tumors; and Consumer Health, featuring IM8 Health, a supplement and wellness brand, and Europa, a sports nutrition distribution company.
What is the latest news on PRE?
The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation". Prenetics announced it will report its Q2 2026 financial results on August 18, 2026, host a live-stream earnings event on Stocktwits, and disclosed upcoming conference participation.